|
CN104136458A
(zh)
|
2012-02-22 |
2014-11-05 |
宾夕法尼亚大学董事会 |
在第二代嵌合抗原受体中cd2信号传导结构域的使用
|
|
SG11201502598SA
(en)
*
|
2012-10-02 |
2015-05-28 |
Sloan Kettering Inst Cancer |
Compositions and methods for immunotherapy
|
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
ES2949648T3
(es)
|
2012-12-20 |
2023-10-02 |
Purdue Research Foundation |
Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
US9511092B2
(en)
|
2013-01-28 |
2016-12-06 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
|
|
CN105101803A
(zh)
*
|
2013-02-06 |
2015-11-25 |
人类起源公司 |
具有改进特异性的修饰的t淋巴细胞
|
|
HRP20201419T1
(hr)
|
2013-02-26 |
2020-12-11 |
Memorial Sloan Kettering Cancer Center |
Pripravci i postupci za imunoterapiju
|
|
CA2907397C
(en)
|
2013-03-15 |
2022-11-22 |
Anthrogenesis Corporation |
Modified t lymphocytes
|
|
EP3789487A1
(en)
*
|
2013-04-03 |
2021-03-10 |
Memorial Sloan Kettering Cancer Center |
Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
|
|
EP3105333B1
(en)
*
|
2014-02-10 |
2020-04-08 |
Emory University |
Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
|
|
JP6788573B6
(ja)
|
2014-04-10 |
2020-12-16 |
シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート |
メトトレキサートによる選択と組み合わせたＳｌｅｅｐｉｎｇ Ｂｅａｕｔｙトランスポゾンによる遺伝子改変Ｔ細胞の製造
|
|
ES2759260T3
(es)
|
2014-04-23 |
2020-05-08 |
Juno Therapeutics Inc |
Métodos para aislar, cultivar y modificar genéticametne poblaciones de células inmunes para la terapia adoptiva
|
|
DK3134095T3
(da)
|
2014-04-25 |
2020-06-29 |
Bluebird Bio Inc |
Forbedrede fremgangsmåder til fremstilling af adoptive celleterapier
|
|
RU2708311C2
(ru)
|
2014-04-25 |
2019-12-05 |
Блубёрд Био, Инк. |
Химерные антигенные рецепторы с mnd-промотором
|
|
KR20210014210A
(ko)
|
2014-05-15 |
2021-02-08 |
내셔널 유니버시티 오브 싱가포르 |
변형된 천연 살해 세포 및 그의 용도
|
|
SI3151672T1
(sl)
*
|
2014-06-06 |
2021-03-31 |
Bluebird Bio, Inc. |
Izboljšani T-celični sestavki
|
|
CN107106665A
(zh)
|
2014-06-06 |
2017-08-29 |
纪念斯隆-凯特琳癌症中心 |
靶向间皮素的嵌合抗原受体及其用途
|
|
CN107075483A
(zh)
|
2014-07-15 |
2017-08-18 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗的工程改造的细胞
|
|
KR102612313B1
(ko)
|
2014-07-21 |
2023-12-12 |
노파르티스 아게 |
인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
|
|
US9777061B2
(en)
|
2014-07-21 |
2017-10-03 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
|
US20170226216A1
(en)
|
2014-07-24 |
2017-08-10 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
|
WO2016022994A2
(en)
|
2014-08-08 |
2016-02-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
High affinity pd-1 agents and methods of use
|
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
|
ES2688035T3
(es)
*
|
2014-08-29 |
2018-10-30 |
Gemoab Monoclonals Gmbh |
Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
|
|
IL293714A
(en)
|
2014-10-20 |
2022-08-01 |
Juno Therapeutics Inc |
Methods and preparations for dosing in stress cell therapy
|
|
US20170258835A1
(en)
*
|
2014-10-31 |
2017-09-14 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for modified t cells
|
|
CN107109438B
(zh)
*
|
2014-11-05 |
2021-09-03 |
朱诺治疗学股份有限公司 |
用于转导及细胞处理的方法
|
|
CN107206025A
(zh)
|
2014-12-03 |
2017-09-26 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗的方法和组合物
|
|
EP3640262A1
(en)
|
2014-12-12 |
2020-04-22 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors for use in the treatment of a hematological malignancy
|
|
IL301458A
(en)
*
|
2014-12-24 |
2023-05-01 |
Autolus Ltd |
A cell that simultaneously expresses a chimeric antigen receptor (CAR) of 19CD and 22CD
|
|
MA41346A
(fr)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
Eléments régulateurs post-transcriptionnels d'hépatite modifiée
|
|
AR103442A1
(es)
|
2015-01-16 |
2017-05-10 |
Juno Therapeutics Inc |
Anticuerpos y receptores de antígenos quiméricos específicos de ror1
|
|
JP6800859B2
(ja)
|
2015-01-26 |
2020-12-16 |
フェイト セラピューティクス，インコーポレイテッド |
造血細胞分化を誘導するための方法および組成物
|
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
AU2016222887B2
(en)
|
2015-02-24 |
2022-07-14 |
The Regents Of The University Of California |
Binding-triggered transcriptional switches and methods of use thereof
|
|
ES2923895T3
(es)
|
2015-02-27 |
2022-10-03 |
Icell Gene Therapeutics Llc |
Receptores de antígeno quimérico (CARS) dirigidos a neoplasisas malignas hematológicas, composiciones y métodos de uso de los mismos
|
|
AU2016243043B2
(en)
*
|
2015-04-02 |
2021-12-09 |
Memorial Sloan Kettering Cancer Center |
TNFRSF14/ HVEM proteins and methods of use thereof
|
|
CN119925616A
(zh)
|
2015-04-08 |
2025-05-06 |
诺华股份有限公司 |
Cd20疗法、cd22疗法和与cd19嵌合抗原受体（car）表达细胞的联合疗法
|
|
MX2017013247A
(es)
|
2015-04-15 |
2018-08-15 |
Prospect Chartercare Rwmc Llc D/B/A Roger Williams Medical Center |
Infusion arterial hepatica de linfocitos t car.
|
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
|
ES2948133T3
(es)
|
2015-04-17 |
2023-08-31 |
Novartis Ag |
Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
|
|
US10786549B2
(en)
|
2015-04-23 |
2020-09-29 |
Baylor College Of Medicine |
CD5 chimeric antigen receptor for adoptive T cell therapy
|
|
MX2017013668A
(es)
|
2015-04-25 |
2018-07-06 |
Massachusetts Gen Hospital |
Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
|
|
JP2018515123A
(ja)
|
2015-05-18 |
2018-06-14 |
ティーシーアール２ セラピューティクス インク． |
融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
|
|
WO2016196388A1
(en)
|
2015-05-29 |
2016-12-08 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
|
WO2016201304A1
(en)
|
2015-06-10 |
2016-12-15 |
Nantkwest, Inc. |
Modified nk-92 cells for treating cancer
|
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
|
CN107849112B
(zh)
|
2015-06-25 |
2022-04-01 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(car)、组合物及其使用方法
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
TWI859112B
(zh)
*
|
2015-07-21 |
2024-10-21 |
瑞士商諾華公司 |
改良免疫細胞之功效及擴展之方法
|
|
WO2017023859A1
(en)
|
2015-07-31 |
2017-02-09 |
Memorial Sloan-Kettering Cancer Center |
Antigen-binding proteins targeting cd56 and uses thereof
|
|
GB201513540D0
(en)
|
2015-07-31 |
2015-09-16 |
King S College London |
Therapeutic agents
|
|
CA2994829A1
(en)
|
2015-08-07 |
2017-02-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Bispecific car t-cells for solid tumor targeting
|
|
CN105087495B
(zh)
*
|
2015-08-21 |
2016-04-27 |
深圳市茵冠生物科技有限公司 |
双嵌合抗原受体修饰的t淋巴细胞及其制备方法
|
|
AU2016316033B2
(en)
|
2015-09-04 |
2022-03-03 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of use
|
|
CN108348606A
(zh)
|
2015-09-18 |
2018-07-31 |
综合医院公司以麻省总医院名义经营 |
用于治疗癌症的抗趋除剂的局部递送
|
|
EP3662930A1
(en)
|
2015-09-24 |
2020-06-10 |
AbVitro LLC |
Hiv antibody compositions and methods of use
|
|
CN105924529B
(zh)
*
|
2015-10-13 |
2019-08-06 |
中国人民解放军总医院 |
嵌合抗原受体及其基因和重组表达载体、car138-nkt细胞及其制备方法和应用
|
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
|
RU2761555C2
(ru)
|
2015-10-22 |
2021-12-09 |
Джуно Терапьютикс Гмбх |
Способы, наборы, средства и устройства для трансдукции
|
|
JP7316042B2
(ja)
|
2015-10-23 |
2023-07-27 |
ユーリカ セラピューティックス， インコーポレイテッド |
抗体／ｔ細胞受容体キメラ構築物およびその使用
|
|
JP7534070B2
(ja)
|
2015-11-04 |
2024-08-14 |
フェイト セラピューティクス，インコーポレイテッド |
造血細胞分化を誘導するための方法および組成物
|
|
CN108368520B
(zh)
|
2015-11-04 |
2023-01-17 |
菲特治疗公司 |
多能细胞的基因组工程改造
|
|
US11020429B2
(en)
|
2015-11-05 |
2021-06-01 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
|
MA44314A
(fr)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
|
MA43380A
(fr)
|
2015-12-03 |
2018-10-10 |
Juno Therapeutics Inc |
Récepteurs chimériques modifiés et compositions et procédés associés
|
|
US20200297760A1
(en)
|
2015-12-03 |
2020-09-24 |
Juno Therapeutics, Inc. |
Compositions and methods for reducing immune responses against chimeric antigen receptors
|
|
CA3006432A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
EP3384294B1
(en)
|
2015-12-04 |
2021-10-13 |
Juno Therapeutics, Inc. |
Methods and compositions related to toxicity associated with cell therapy
|
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
|
WO2017112877A1
(en)
*
|
2015-12-22 |
2017-06-29 |
Icell Gene Therapeutics, Llc |
Chimeric antigen receptors and enhancement of anti-tumor activity
|
|
WO2017120501A1
(en)
|
2016-01-07 |
2017-07-13 |
Mayo Foundation For Medical Education And Research |
Methods of treating cancer with interferon
|
|
US20190287013A1
(en)
|
2016-03-16 |
2019-09-19 |
Juno Therapeutics, Inc. |
Methods for determining dosing of a therapeutic agent and related treatments
|
|
EP3430549A1
(en)
|
2016-03-16 |
2019-01-23 |
Juno Therapeutics, Inc. |
Methods for adaptive design of a treatment regimen and related treatments
|
|
MA71266A
(fr)
|
2016-03-22 |
2025-04-30 |
Seattle Children's Hospital(DBA Seattle Children's Research Institute) |
Procédés d'intervention précoce pour prévenir ou améliorer la toxicité
|
|
EP3436480A4
(en)
|
2016-03-30 |
2019-11-27 |
Musc Foundation for Research Development |
METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
|
|
WO2017177149A2
(en)
|
2016-04-08 |
2017-10-12 |
Purdue Research Foundation |
Methods and compositions for car t cell therapy
|
|
US11400116B2
(en)
|
2016-05-06 |
2022-08-02 |
The Regents Of The University Of California |
Systems and methods for targeting cancer cells
|
|
JP2019517788A
(ja)
|
2016-05-06 |
2019-06-27 |
ジュノー セラピューティクス インコーポレイテッド |
遺伝子操作された細胞および同細胞を作製する方法
|
|
SG11201809542XA
(en)
*
|
2016-05-25 |
2018-12-28 |
Council Queensland Inst Medical Res |
Methods of immunotherapy
|
|
CN109689677B
(zh)
|
2016-05-27 |
2023-11-10 |
阿迪根有限公司 |
用于基因组编辑分子的细胞内递送的肽和纳米颗粒
|
|
EP4011381A1
(en)
|
2016-06-03 |
2022-06-15 |
Memorial Sloan-Kettering Cancer Center |
Adoptive cell therapies as early treatment options
|
|
MA45341A
(fr)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
|
EP4353750A3
(en)
|
2016-06-24 |
2024-07-24 |
iCell Gene Therapeutics LLC |
Chimeric antigen receptors (cars), compositions and methods thereof
|
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
|
JP6987134B2
(ja)
|
2016-06-27 |
2021-12-22 |
ジュノー セラピューティクス インコーポレイテッド |
ペプチドエピトープを同定する方法、そのようなエピトープに結合する分子および関連用途
|
|
WO2018022646A1
(en)
*
|
2016-07-25 |
2018-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing modified natural killer cells and methods of use
|
|
US11421287B2
(en)
|
2016-07-29 |
2022-08-23 |
Juno Therapeutics, Inc. |
Methods for assessing the presence or absence of replication competent virus
|
|
MA45784A
(fr)
|
2016-07-29 |
2019-06-05 |
Juno Therapeutics Inc |
Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps
|
|
JP7295795B2
(ja)
|
2016-07-29 |
2023-06-21 |
ジュノー セラピューティクス インコーポレイテッド |
免疫調節ポリペプチドならびに関連する組成物および方法
|
|
EP3494138A1
(en)
|
2016-08-02 |
2019-06-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US12350349B2
(en)
|
2016-08-03 |
2025-07-08 |
Washington University |
Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
|
|
WO2018027197A1
(en)
*
|
2016-08-04 |
2018-02-08 |
Memorial Sloan-Kettering Cancer Center |
Cancer antigen targets and uses thereof
|
|
JP7500195B2
(ja)
|
2016-08-23 |
2024-06-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法
|
|
CA3034691A1
(en)
|
2016-08-30 |
2018-03-08 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of use for treating viral and other infections
|
|
RU2021123536A
(ru)
|
2016-09-12 |
2022-01-14 |
Джуно Терапьютикс, Инк. |
Сборочные узлы перфузионных биореакторных мешков
|
|
CA3038897A1
(en)
|
2016-09-28 |
2018-04-05 |
Atossa Genetics Inc. |
Methods of adoptive cell therapy
|
|
MX2019003768A
(es)
|
2016-10-03 |
2019-06-24 |
Juno Therapeutics Inc |
Moleculas de enlace especificas de hpv.
|
|
IL292551B2
(en)
|
2016-10-07 |
2023-10-01 |
Tcr2 Therapeutics Inc |
Preparations and methods for reprogramming T-cell receptors using fusion proteins
|
|
SG11201903282TA
(en)
|
2016-10-13 |
2019-05-30 |
Juno Therapeutics Inc |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
|
US20190298772A1
(en)
|
2016-11-03 |
2019-10-03 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell-based therapy and a btk inhibitor
|
|
MA46716A
(fr)
|
2016-11-03 |
2019-09-11 |
Juno Therapeutics Inc |
Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
|
|
AU2017355504C1
(en)
|
2016-11-04 |
2024-06-20 |
2Seventy Bio, Inc. |
Anti-BCMA CAR T cell compositions
|
|
AU2017363311A1
(en)
|
2016-11-22 |
2019-06-13 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
WO2018102612A1
(en)
|
2016-12-02 |
2018-06-07 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
|
KR20190104528A
(ko)
|
2016-12-03 |
2019-09-10 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Car-t 세포들 투여를 결정하는 방법
|
|
JP2020511462A
(ja)
|
2016-12-03 |
2020-04-16 |
ジュノー セラピューティクス インコーポレイテッド |
キナーゼ阻害剤との組み合わせで治療用ｔ細胞を使用するための方法および組成物
|
|
MX2019006285A
(es)
|
2016-12-03 |
2019-12-16 |
Juno Therapeutics Inc |
Metodos para modulacion de celulas cart-t.
|
|
MA46998A
(fr)
|
2016-12-05 |
2019-10-09 |
Juno Therapeutics Inc |
Production de cellules modifiées pour une thérapie cellulaire adoptive
|
|
AU2017375630B2
(en)
|
2016-12-12 |
2023-12-21 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
|
EP3336107A1
(en)
|
2016-12-15 |
2018-06-20 |
Miltenyi Biotec GmbH |
Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
|
|
CN106749677B
(zh)
*
|
2017-01-04 |
2020-06-12 |
上海交通大学医学院附属瑞金医院 |
一种靶向mll白血病的双特异性嵌合抗原受体基因及其应用
|
|
US11821027B2
(en)
|
2017-01-10 |
2023-11-21 |
Juno Therapeutics, Inc. |
Epigenetic analysis of cell therapy and related methods
|
|
JP2020505034A
(ja)
|
2017-01-20 |
2020-02-20 |
ジュノ セラピューティクス ゲーエムベーハー |
細胞表面コンジュゲートならびに関連する細胞組成物および方法
|
|
CA3052779A1
(en)
|
2017-02-17 |
2018-08-23 |
Fred Hutchinson Cancer Research Center |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
ES2988795T3
(es)
|
2017-02-27 |
2024-11-21 |
Juno Therapeutics Inc |
Composiciones, artículos de fabricación y métodos relacionados con la dosificación en terapia celular
|
|
ES3010559T3
(en)
|
2017-02-28 |
2025-04-03 |
Endocyte Inc |
Compositions and methods for car t cell therapy
|
|
EP3592368A1
(en)
|
2017-03-08 |
2020-01-15 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of use
|
|
CN110913690A
(zh)
|
2017-03-14 |
2020-03-24 |
朱诺治疗学股份有限公司 |
用于低温储存的方法
|
|
CA3056542A1
(en)
|
2017-03-15 |
2018-09-20 |
Oxford Biomedica (Uk) Limited |
Method
|
|
SG11201907434RA
(en)
|
2017-03-22 |
2019-10-30 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
WO2018175676A1
(en)
|
2017-03-23 |
2018-09-27 |
The General Hospital Corporation |
Cxcr4/cxcr7 blockade and treatment of human papilloma virus-associated disease
|
|
BR112019020001A2
(pt)
|
2017-03-27 |
2020-04-28 |
Nat Univ Singapore |
linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais
|
|
IL269553B2
(en)
|
2017-03-27 |
2025-10-01 |
Nat Univ Singapore |
Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
|
|
RU2740438C1
(ru)
|
2017-04-05 |
2021-01-14 |
Корея Рисерч Инститьют Оф Байосайенс Энд Байотекнолоджи |
Активирующий nk-клетки слитый белок, nk-клетки и фармацевтическая композиция, включающая их
|
|
AU2018250336B2
(en)
|
2017-04-07 |
2025-02-20 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
|
|
MX2019012189A
(es)
|
2017-04-14 |
2020-12-10 |
Juno Therapeutics Inc |
Metodos para valorar la glucosilacion de la superficie celular.
|
|
EP4083063A3
(en)
|
2017-04-18 |
2023-01-04 |
FUJIFILM Cellular Dynamics, Inc. |
Antigen-specific immune effector cells
|
|
CA3059753A1
(en)
*
|
2017-04-26 |
2018-11-01 |
Eureka Therapeutics, Inc. |
Chimeric antibody/t-cell receptor constructs and uses thereof
|
|
CN111032850B
(zh)
|
2017-04-27 |
2024-08-13 |
朱诺治疗学有限公司 |
寡聚粒子试剂及其使用方法
|
|
KR20240139092A
(ko)
|
2017-05-01 |
2024-09-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 요법 및 면역조절 화합물의 조합
|
|
AU2018275891B2
(en)
|
2017-06-02 |
2025-02-27 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
|
CN111225675B
(zh)
|
2017-06-02 |
2024-05-03 |
朱诺治疗学股份有限公司 |
使用过继细胞疗法治疗的制品和方法
|
|
SG11201912455VA
(en)
|
2017-06-20 |
2020-01-30 |
Inst Curie |
Immune cells defective for suv39h1
|
|
JP2020524512A
(ja)
|
2017-06-21 |
2020-08-20 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
|
|
KR20200019231A
(ko)
|
2017-06-22 |
2020-02-21 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
조절 면역 세포를 제조하기 위한 방법 및 이의 용도
|
|
JP2020526194A
(ja)
|
2017-06-29 |
2020-08-31 |
ジュノー セラピューティクス インコーポレイテッド |
免疫療法薬と関連する毒性を評価するためのマウスモデル
|
|
US12178830B2
(en)
|
2017-06-30 |
2024-12-31 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for adoptive cell therapy for cancer
|
|
CN118206655A
(zh)
|
2017-07-25 |
2024-06-18 |
得克萨斯大学体系董事会 |
增强的嵌合抗原受体及其用途
|
|
WO2019027850A1
(en)
|
2017-07-29 |
2019-02-07 |
Juno Therapeutics, Inc. |
CELL EXPANSION REAGENTS EXPRESSING RECOMBINANT RECEPTORS
|
|
CN107326014B
(zh)
*
|
2017-07-31 |
2019-09-24 |
时力生物科技（北京）有限公司 |
一种双特异性嵌合抗原受体修饰的t淋巴细胞及其制备方法和应用
|
|
BR112020001601A2
(pt)
|
2017-08-09 |
2020-08-11 |
Juno Therapeutics Inc |
métodos e composições para preparar células geneticamente manipuladas
|
|
CA3070579A1
(en)
|
2017-08-09 |
2019-02-14 |
Juno Therapeutics, Inc. |
Methods for producing genetically engineered cell compositions and related compositions
|
|
EP3676403A1
(en)
|
2017-09-01 |
2020-07-08 |
Juno Therapeutics, Inc. |
Gene expression and assessment of risk of developing toxicity following cell therapy
|
|
EP3679370A1
(en)
|
2017-09-07 |
2020-07-15 |
Juno Therapeutics, Inc. |
Methods of identifying cellular attributes related to outcomes associated with cell therapy
|
|
CN109517820B
(zh)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
一种靶向HPK1的gRNA以及HPK1基因编辑方法
|
|
MX2020003536A
(es)
|
2017-10-03 |
2020-09-14 |
Juno Therapeutics Inc |
Moleculas de union especifica a virus de papiloma humano (hpv).
|
|
CA3081336A1
(en)
|
2017-10-12 |
2019-04-18 |
Gregory LIZEE |
T cell receptors for immunotherapy
|
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
EP3704229B1
(en)
|
2017-11-01 |
2023-12-20 |
Juno Therapeutics, Inc. |
Process for producing a t cell composition
|
|
US11564946B2
(en)
|
2017-11-01 |
2023-01-31 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
|
AU2018358067A1
(en)
|
2017-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
|
|
WO2019089884A2
(en)
|
2017-11-01 |
2019-05-09 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
|
US11066475B2
(en)
|
2017-11-01 |
2021-07-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
|
|
PL3704230T3
(pl)
|
2017-11-01 |
2025-02-24 |
Juno Therapeutics, Inc. |
Proces wytwarzania kompozycji terapeutycznych z komórek zmodyfikowanych genetycznie
|
|
CA3080109A1
(en)
|
2017-11-03 |
2019-05-09 |
Sorrento Therapeutics, Inc. |
Cd38-directed chimeric antigen receptor constructs
|
|
CN111886012A
(zh)
|
2017-11-06 |
2020-11-03 |
朱诺治疗学股份有限公司 |
细胞疗法与γ分泌酶抑制剂的组合
|
|
EP3707258A1
(en)
|
2017-11-06 |
2020-09-16 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of cblb in t cells for immunotherapy
|
|
CN111556789A
(zh)
|
2017-11-10 |
2020-08-18 |
朱诺治疗学股份有限公司 |
封闭系统低温器皿
|
|
JP2021502829A
(ja)
*
|
2017-11-14 |
2021-02-04 |
メモリアル スローン ケタリング キャンサー センター |
Ｉｌ−３６を分泌する免疫応答性細胞およびその使用
|
|
KR20200116081A
(ko)
|
2017-12-01 |
2020-10-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
유전자 조작된 세포의 투약 및 조절 방법
|
|
CN111587254B
(zh)
|
2017-12-05 |
2025-02-25 |
特拉维夫医疗中心医学研究基础设施及卫生服务基金 |
包含抗cd38和抗cd138嵌合抗原受体的t-细胞及其用途
|
|
WO2019111250A1
(en)
|
2017-12-05 |
2019-06-13 |
The Medical Research Infrastructure And Health Services Fund Of The Tel Aviv Medical Center |
T-cells comprising two different chimeric antigen receptors and uses thereof
|
|
MX2020005908A
(es)
|
2017-12-08 |
2020-10-07 |
Juno Therapeutics Inc |
Proceso para producir una composicion de celulas t modificadas.
|
|
JP7433230B2
(ja)
|
2017-12-08 |
2024-02-19 |
ジュノー セラピューティクス インコーポレイテッド |
細胞を培養するための無血清培地配合物およびその使用の方法
|
|
KR20250141843A
(ko)
|
2017-12-08 |
2025-09-29 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 요법을 위한 표현형 마커 및 관련 방법
|
|
KR20200110745A
(ko)
|
2017-12-15 |
2020-09-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
항 - ｃｃｔ5 결합 분자 및 이의 사용 방법
|
|
CN109988242A
(zh)
*
|
2018-01-02 |
2019-07-09 |
武汉波睿达生物科技有限公司 |
联合嵌合抗原受体、表达载体、慢病毒及t细胞
|
|
CN111867619A
(zh)
|
2018-01-03 |
2020-10-30 |
曲生物制品公司 |
过继性细胞治疗的先天寻靶
|
|
WO2019139972A1
(en)
|
2018-01-09 |
2019-07-18 |
Board Of Regents, The University Of Texas System |
T cell receptors for immunotherapy
|
|
WO2019141270A1
(zh)
*
|
2018-01-19 |
2019-07-25 |
科济生物医药（上海）有限公司 |
SynNotch受体调控表达IL12
|
|
TW201940182A
(zh)
|
2018-01-22 |
2019-10-16 |
美商安德賽特公司 |
Car t 細胞之使用方法
|
|
JP2021511802A
(ja)
|
2018-01-31 |
2021-05-13 |
ジュノー セラピューティクス インコーポレイテッド |
複製可能ウイルスの存在または非存在を評価するための方法および試薬
|
|
WO2019152743A1
(en)
|
2018-01-31 |
2019-08-08 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
|
CN108314739B
(zh)
*
|
2018-02-05 |
2020-07-14 |
深圳市默赛尔生物医学科技发展有限公司 |
多信号嵌合抗原受体及其表达基因、其修饰的nk细胞及应用
|
|
JP7360174B2
(ja)
|
2018-02-09 |
2023-10-12 |
ナショナル ユニヴァーシティー オブ シンガポール |
ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
|
|
WO2019157454A1
(en)
|
2018-02-11 |
2019-08-15 |
Memorial Sloan-Kettering Cancer Center |
Non-hla restricted t cell receptors and uses thereof
|
|
CN112041432A
(zh)
|
2018-02-15 |
2020-12-04 |
纪念斯隆-凯特林癌症中心 |
Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
|
|
JP7568224B2
(ja)
|
2018-02-23 |
2024-10-16 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞療法のための配列決定法
|
|
US20210046159A1
(en)
|
2018-03-09 |
2021-02-18 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
|
CN119770648A
(zh)
|
2018-03-09 |
2025-04-08 |
克莱格医学有限公司 |
用于治疗肿瘤的方法和组合物
|
|
CN112888709B
(zh)
*
|
2018-03-30 |
2024-10-29 |
优瑞科生物技术公司 |
标靶cd22的构建体和其用途
|
|
JP7334985B2
(ja)
|
2018-04-02 |
2023-08-29 |
ナショナル ユニヴァーシティー オブ シンガポール |
免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
|
|
JP7589047B2
(ja)
|
2018-04-05 |
2024-11-25 |
ジュノー セラピューティクス インコーポレイテッド |
組換え受容体を発現する細胞の作製方法および関連組成物
|
|
RU2020135968A
(ru)
|
2018-04-05 |
2022-05-06 |
Джуно Терапьютикс, Инк. |
T-клеточные рецепторы и модифицированные клетки, экспрессирующие
|
|
KR20210020873A
(ko)
|
2018-04-05 |
2021-02-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 τ 세포, 관련 폴리뉴클레오티드 및 방법
|
|
SG11202010262TA
(en)
|
2018-04-19 |
2020-11-27 |
Baylor College Medicine |
Reprogramming cd4 t cells into cytotoxic cd8 cells by forced expression of cd8ab and class 1 restricted t cell receptors
|
|
CN108864288A
(zh)
*
|
2018-04-26 |
2018-11-23 |
上海怡豪生物科技有限公司 |
乳腺癌的双靶点car-t治疗载体及其构建方法和应用
|
|
KR20210044736A
(ko)
|
2018-05-03 |
2021-04-23 |
주노 쎄러퓨티크스 인코퍼레이티드 |
키메라 항원 수용체(ｃａｒ) ｔ세포 요법과 키나제 억제제의 조합요법
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
CN112469440B
(zh)
*
|
2018-06-18 |
2024-09-06 |
优瑞科生物技术公司 |
靶向前列腺特异性膜抗原(psma)的构建体和其用途
|
|
CN110615843B
(zh)
*
|
2018-06-20 |
2023-05-09 |
上海隆耀生物科技有限公司 |
一种包含第三信号受体的嵌合抗原受体及其应用
|
|
EP3834849A4
(en)
|
2018-07-24 |
2022-08-03 |
CRAGE medical Co., Limited |
Method for treating tumor using immune effector cell
|
|
KR20210059715A
(ko)
|
2018-08-09 |
2021-05-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
통합된 핵산 평가 방법
|
|
EP3833742A2
(en)
|
2018-08-09 |
2021-06-16 |
Juno Therapeutics, Inc. |
Processes for generating engineered cells and compositions thereof
|
|
AU2019330347B2
(en)
|
2018-08-29 |
2025-07-24 |
National University Of Singapore |
A method to specifically stimulate survival and expansion of genetically-modified immune cells
|
|
EP3847266A1
(en)
*
|
2018-09-05 |
2021-07-14 |
GlaxoSmithKline Intellectual Property Development Ltd |
T cell modification
|
|
SG11202102108QA
(en)
|
2018-09-11 |
2021-04-29 |
Juno Therapeutics Inc |
Methods for mass spectrometry analysis of engineered cell compositions
|
|
CN112739816B
(zh)
|
2018-09-19 |
2025-09-12 |
富士胶片细胞动力公司 |
用于激活和扩增嵌合抗原受体-修饰的免疫细胞的蛋白l
|
|
CN113227358A
(zh)
|
2018-10-31 |
2021-08-06 |
朱诺治疗学有限公司 |
选择并刺激细胞的方法及用于所述方法的设备
|
|
BR112021008289A2
(pt)
|
2018-11-01 |
2021-10-26 |
Juno Therapeutics, Inc. |
Métodos para tratamento utilizando receptores de antígeno quimérico específico para antígeno de maturação de célula b
|
|
TW202021981A
(zh)
|
2018-11-01 |
2020-06-16 |
美商奇諾治療有限公司 |
G蛋白偶合受體c類第5群成員d（gprc5d）特異性嵌合抗原受體
|
|
WO2020097132A1
(en)
|
2018-11-06 |
2020-05-14 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered t cells
|
|
BR112021008930A2
(pt)
|
2018-11-08 |
2021-11-03 |
Juno Therapeutics Inc |
Métodos e combinações para o tratamento e modulação de célula t
|
|
JP2022513062A
(ja)
|
2018-11-16 |
2022-02-07 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂ細胞悪性腫瘍を処置するために、操作されたｔ細胞を投薬する方法
|
|
JP7630832B2
(ja)
|
2018-11-19 |
2025-02-18 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
Ｃａｒおよびｔｃｒ形質導入用のモジュール式ポリシストロニックベクター
|
|
WO2020113029A2
(en)
|
2018-11-28 |
2020-06-04 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
|
CN113316455A
(zh)
|
2018-11-29 |
2021-08-27 |
得克萨斯大学体系董事会 |
用于离体扩增自然杀伤细胞的方法及其用途
|
|
KR20210110811A
(ko)
|
2018-11-30 |
2021-09-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법에서 ｂ 세포 악성 종양의 투약 및 치료 방법
|
|
CN113710256A
(zh)
|
2018-11-30 |
2021-11-26 |
朱诺治疗学股份有限公司 |
使用过继细胞疗法的治疗方法
|
|
MX2021009087A
(es)
|
2019-01-29 |
2021-09-08 |
Juno Therapeutics Inc |
Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1).
|
|
WO2020163755A1
(en)
*
|
2019-02-08 |
2020-08-13 |
Dna Twopointo Inc. |
Transposon-based modifications of immune cells
|
|
EP3927735A4
(en)
*
|
2019-02-18 |
2023-09-06 |
Memorial Sloan Kettering Cancer Center |
COMBINATIONS OF MULTIPLE CHIMERIC ANTIGEN RECEPTORS FOR IMMUNOTHERAPY
|
|
GB201902277D0
(en)
|
2019-02-19 |
2019-04-03 |
King S College London |
Therapeutic agents
|
|
WO2020180882A1
(en)
|
2019-03-05 |
2020-09-10 |
Nkarta, Inc. |
Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
EP3941493A4
(en)
*
|
2019-03-22 |
2022-12-28 |
The Regents of the University of California |
SWITCHABLE CHIMERA ANTIGEN RECEPTOR MANIPULATED HUMAN NATURAL KILLER CELLS
|
|
US20220184129A1
(en)
*
|
2019-04-12 |
2022-06-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins
|
|
TW202110873A
(zh)
|
2019-04-30 |
2021-03-16 |
美商聖堤生物科技股份有限公司 |
嵌合受體及其使用方法
|
|
SG11202111360YA
(en)
|
2019-05-01 |
2021-11-29 |
Juno Therapeutics Inc |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
CA3136742A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
EP3980530A1
(en)
|
2019-06-07 |
2022-04-13 |
Juno Therapeutics, Inc. |
Automated t cell culture
|
|
CN114269371A
(zh)
|
2019-06-12 |
2022-04-01 |
朱诺治疗学股份有限公司 |
细胞介导的细胞毒性疗法与促存活bcl2家族蛋白的抑制剂的组合疗法
|
|
EP4003407A1
(en)
|
2019-07-23 |
2022-06-01 |
Mnemo Therapeutics |
Immune cells defective for suv39h1
|
|
KR20220066892A
(ko)
|
2019-08-22 |
2022-05-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｔ 세포 요법 및 제스트 동족체 2의 인핸서 (ｅｚｈ2) 억제제의 병용 요법 및 관련 방법
|
|
EP4021485A1
(en)
*
|
2019-08-28 |
2022-07-06 |
King's College London |
B cell targeted parallel car (pcar) therapeutic agents
|
|
EP4022637A2
(en)
|
2019-08-30 |
2022-07-06 |
Juno Therapeutics, Inc. |
Machine learning methods for classifying cells
|
|
WO2021043804A1
(en)
|
2019-09-02 |
2021-03-11 |
Institut Curie |
Immunotherapy targeting tumor neoantigenic peptides
|
|
EP4048304A1
(en)
|
2019-10-22 |
2022-08-31 |
Institut Curie |
Immunotherapy targeting tumor neoantigenic peptides
|
|
BR112022008023A2
(pt)
|
2019-10-30 |
2022-07-12 |
Juno Therapeutics Gmbh |
Dispositivos de seleção e/ou estimulação de células e métodos de uso
|
|
US20220412954A1
(en)
|
2019-11-05 |
2022-12-29 |
Juno Therapeutics, Inc. |
Methods of determining attributes of therapeutic t cell compositions
|
|
AU2020379043A1
(en)
|
2019-11-07 |
2022-06-02 |
Juno Therapeutics, Inc. |
Combination of a T cell therapy and (S)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione
|
|
AU2020394441B2
(en)
|
2019-11-26 |
2025-11-13 |
Novartis Ag |
CD19 and CD22 chimeric antigen receptors and uses thereof
|
|
JP2023504740A
(ja)
|
2019-12-06 |
2023-02-06 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂｃｍａ標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
|
|
MX2022006715A
(es)
|
2019-12-06 |
2022-09-23 |
Juno Therapeutics Inc |
Metodos relacionados con toxicidad y respuesta asociada con terapia celular para tratar neoplasias malignas de celulas b.
|
|
US20230192869A1
(en)
|
2019-12-06 |
2023-06-22 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
|
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
|
WO2021151008A1
(en)
|
2020-01-24 |
2021-07-29 |
Juno Therapuetics, Inc. |
Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
|
|
US20230090117A1
(en)
|
2020-01-28 |
2023-03-23 |
Juno Therapeutics, Inc. |
Methods for t cell transduction
|
|
AU2021220875A1
(en)
|
2020-02-12 |
2022-09-29 |
Juno Therapeutics, Inc. |
CD19-directed chimeric antigen receptor T cell compositions and methods and uses thereof
|
|
IL295381A
(en)
|
2020-02-12 |
2022-10-01 |
Juno Therapeutics Inc |
bcma-directed chimeric t-cell antigen receptor compounds and methods and uses thereof
|
|
EP4107173A1
(en)
|
2020-02-17 |
2022-12-28 |
Board of Regents, The University of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
|
US20230076164A1
(en)
*
|
2020-02-17 |
2023-03-09 |
Miltenyi Biotec B.V. & Co. KG |
Method for providing personalized cells with chimeric antigen receptors (CAR) against tumor microenvironment cells
|
|
WO2021207689A2
(en)
|
2020-04-10 |
2021-10-14 |
Juno Therapeutics, Inc. |
Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
|
|
BR112022021788A2
(pt)
|
2020-04-28 |
2023-01-17 |
Juno Therapeutics Inc |
Combinação de terapia com células t direcionada para bcma e um composto imunomodulador
|
|
WO2021228999A1
(en)
|
2020-05-12 |
2021-11-18 |
Institut Curie |
Neoantigenic epitopes associated with sf3b1 mutations
|
|
JP7727662B2
(ja)
|
2020-05-13 |
2025-08-21 |
ジュノー セラピューティクス インコーポレイテッド |
臨床応答に関連する特徴量の特定方法およびその使用
|
|
WO2021231661A2
(en)
|
2020-05-13 |
2021-11-18 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
|
CN115803084A
(zh)
|
2020-05-21 |
2023-03-14 |
得克萨斯大学体系董事会 |
具有vgll1特异性的t细胞受体和其用途
|
|
JP2023531531A
(ja)
|
2020-06-26 |
2023-07-24 |
ジュノ セラピューティクス ゲーエムベーハー |
組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
|
|
WO2022016119A1
(en)
|
2020-07-17 |
2022-01-20 |
Simurx, Inc. |
Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
|
|
WO2022016112A1
(en)
|
2020-07-17 |
2022-01-20 |
Instil Bio (Uk) Limited |
Receptors providing targeted costimulation for adoptive cell therapy
|
|
JP2023535501A
(ja)
|
2020-07-30 |
2023-08-17 |
アンスティテュ・クリー |
Ｓｏｃｓ１に欠陥のある免疫細胞
|
|
EP4192868A1
(en)
|
2020-08-05 |
2023-06-14 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
|
IL300725A
(en)
|
2020-08-21 |
2023-04-01 |
12343096 Canada Inc |
Modular assembly receivers and their uses
|
|
TW202233673A
(zh)
|
2020-10-23 |
2022-09-01 |
美商雅雪生物治療公司 |
含調節免疫細胞功能之ｃｄ８抗原結合分子之融合物
|
|
JP2023549140A
(ja)
|
2020-11-04 |
2023-11-22 |
マイエロイド・セラピューティクス，インコーポレーテッド |
操作されたキメラ融合タンパク質組成物およびその使用方法
|
|
CN116802203A
(zh)
|
2020-11-04 |
2023-09-22 |
朱诺治疗学股份有限公司 |
从经修饰的恒定cd3免疫球蛋白超家族链基因座表达嵌合受体的细胞、相关多核苷酸和方法
|
|
EP4243839A1
(en)
|
2020-11-13 |
2023-09-20 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
|
AU2021388155A1
(en)
|
2020-11-25 |
2023-06-15 |
Catamaran Bio, Inc. |
Cellular therapeutics engineered with signal modulators and methods of use thereof
|
|
KR20230117167A
(ko)
|
2020-12-02 |
2023-08-07 |
상하이 헨리우스 바이오테크, 인크. |
항GARP/TGFβ항체 및 사용 방법
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
KR20230118887A
(ko)
|
2020-12-03 |
2023-08-14 |
센츄리 쎄라퓨틱스 인코포레이티드 |
유전자 조작 세포 및 이의 용도
|
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
|
JP2024500847A
(ja)
|
2020-12-18 |
2024-01-10 |
センチュリー セラピューティクス，インコーポレイテッド |
適合可能な受容体特異性を有するキメラ抗原受容体システム
|
|
JP2024503027A
(ja)
|
2021-01-11 |
2024-01-24 |
サナ バイオテクノロジー，インコーポレイテッド |
Ｃｄ８標的ウイルスベクターの使用方法
|
|
WO2022187406A1
(en)
|
2021-03-03 |
2022-09-09 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and a dgk inhibitor
|
|
KR20240006721A
(ko)
|
2021-03-11 |
2024-01-15 |
엥스띠뛰 퀴리 |
막 형질 전환 네오 안티젠 펩타이드
|
|
JP2024510981A
(ja)
|
2021-03-11 |
2024-03-12 |
ムネモ・セラピューティクス |
腫瘍ネオ抗原ペプチド及びその使用
|
|
JP2024510982A
(ja)
|
2021-03-11 |
2024-03-12 |
ムネモ・セラピューティクス |
腫瘍ネオ抗原ペプチド
|
|
AU2022237618A1
(en)
|
2021-03-17 |
2023-10-12 |
Create Medicines, Inc. |
Engineered chimeric fusion protein compositions and methods of use thereof
|
|
AU2022244229A1
(en)
|
2021-03-22 |
2023-09-14 |
Juno Therapeutics, Inc. |
Method to assess potency of viral vector particles
|
|
WO2022204070A1
(en)
|
2021-03-22 |
2022-09-29 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
|
IL307257A
(en)
|
2021-03-29 |
2023-11-01 |
Juno Therapeutics Inc |
A combination of car cell therapy and an immunomodulatory compound for the treatment of lymphoma
|
|
AU2022246593A1
(en)
|
2021-03-29 |
2023-10-12 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
|
JP2024514163A
(ja)
|
2021-04-16 |
2024-03-28 |
セルジーン コーポレーション |
Ｂｃｍａ指向性ｔ細胞療法を用いた併用療法
|
|
EP4322991A1
(en)
|
2021-04-16 |
2024-02-21 |
Celgene Corporation |
T cell therapy in patients who have had prior stem cell transplant
|
|
EP4326293A4
(en)
|
2021-04-22 |
2025-03-12 |
Baylor College of Medicine |
METHODS FOR MODIFYING IMMUNE CELLS HAVING REDUCED FRATRICIDAL ACTIVITY
|
|
CN117916256A
(zh)
|
2021-05-06 |
2024-04-19 |
朱诺治疗学有限公司 |
用于刺激和转导t细胞的方法
|
|
EP4337763A1
(en)
|
2021-05-10 |
2024-03-20 |
Institut Curie |
Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
|
|
WO2022241029A1
(en)
|
2021-05-11 |
2022-11-17 |
Myeloid Therapeutics, Inc. |
Methods and compositions for genomic integration
|
|
EP4346912A1
(en)
|
2021-05-25 |
2024-04-10 |
Institut Curie |
Myeloid cells overexpressing bcl2
|
|
TW202306997A
(zh)
|
2021-06-16 |
2023-02-16 |
英商英斯特生物科技有限公司 |
用於在過繼細胞療法中提供標靶共刺激之受體
|
|
WO2023288278A1
(en)
|
2021-07-16 |
2023-01-19 |
Instil Bio (Uk) Limited |
Chimeric molecules providing targeted costimulation for adoptive cell therapy
|
|
TW202321457A
(zh)
|
2021-08-04 |
2023-06-01 |
美商薩那生物科技公司 |
靶向ｃｄ４之病毒載體之用途
|
|
AU2022324040A1
(en)
|
2021-08-04 |
2024-02-22 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
|
CN117836405A
(zh)
*
|
2021-08-13 |
2024-04-05 |
先声创新公司 |
三维培养多能干细胞产生造血干细胞
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
JP2024540320A
(ja)
|
2021-11-03 |
2024-10-31 |
セルジーン コーポレーション |
骨髄腫を処置する際に使用するための、ｂ細胞成熟抗原に特異的なキメラ抗原受容体
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
WO2023105000A1
(en)
|
2021-12-09 |
2023-06-15 |
Zygosity Limited |
Vector
|
|
EP4448775A1
(en)
|
2021-12-17 |
2024-10-23 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
CN118488965A
(zh)
|
2021-12-17 |
2024-08-13 |
上海复宏汉霖生物技术股份有限公司 |
抗ox40抗体、多特异性抗体及其使用方法
|
|
EP4448579A1
(en)
|
2021-12-17 |
2024-10-23 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies and methods of use
|
|
TW202342498A
(zh)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
經修飾副黏液病毒科融合醣蛋白
|
|
EP4456910A1
(en)
|
2021-12-28 |
2024-11-06 |
Mnemo Therapeutics |
Immune cells with inactivated suv39h1 and modified tcr
|
|
CN120077132A
(zh)
|
2022-01-21 |
2025-05-30 |
姆内莫治疗公司 |
Rna对suv39h1表达的调控
|
|
CN119013393A
(zh)
|
2022-01-28 |
2024-11-22 |
朱诺治疗学股份有限公司 |
制造细胞组合物的方法
|
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
CA3243757A1
(en)
|
2022-02-22 |
2023-08-31 |
Juno Therapeutics, Inc. |
CHIMERIC PROTEINASE 3 (PR3) AUTOANTIBODY RECEPTOR T LYMPHOCYTES AND ASSOCIATED METHODS AND USES
|
|
US20250195573A1
(en)
|
2022-03-18 |
2025-06-19 |
The Regents Of The University Of Colorado, A Body Corporate |
Genetically engineered t-cell co-receptors and methods of use thereof
|
|
US20250302930A1
(en)
|
2022-03-24 |
2025-10-02 |
Institut Curie |
Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
|
|
WO2023179740A1
(en)
|
2022-03-25 |
2023-09-28 |
Shanghai Henlius Biotech , Inc. |
Anti-msln antibodies and methods of use
|
|
WO2023187024A1
(en)
|
2022-03-31 |
2023-10-05 |
Institut Curie |
Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
|
|
US20250222027A1
(en)
|
2022-04-01 |
2025-07-10 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
WO2023196921A1
(en)
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Granzyme expressing t cells and methods of use
|
|
US20250304913A1
(en)
|
2022-04-06 |
2025-10-02 |
The Regents Of The University Of Colorado, A Body Corporate |
Chimeric antigen receptor t cells and methods of use thereof
|
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
KR20250008774A
(ko)
|
2022-05-11 |
2025-01-15 |
셀진 코포레이션 |
T 세포 요법 및 그의 생산과 관련된 방법 및 용도
|
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
EP4526332A1
(en)
|
2022-05-16 |
2025-03-26 |
Miltenyi Biotec B.V. & Co. KG |
Endogenous signaling molecule activating chimeric antigen receptors and methods of generation thereof
|
|
EP4279085A1
(en)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
|
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
EP4532695A1
(en)
|
2022-05-25 |
2025-04-09 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
CN115058387B
(zh)
*
|
2022-06-11 |
2023-12-01 |
重庆医科大学 |
一种人胚胎干细胞与前列腺癌细胞共培养制备抗前列腺癌药物的方法
|
|
US20250381272A1
(en)
|
2022-06-22 |
2025-12-18 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
|
JP2025525937A
(ja)
|
2022-08-05 |
2025-08-07 |
ジュノー セラピューティクス インコーポレイテッド |
Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体
|
|
AU2023329484A1
(en)
|
2022-08-26 |
2025-02-20 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
|
|
CN120152717A
(zh)
|
2022-09-08 |
2025-06-13 |
朱诺治疗学股份有限公司 |
T细胞疗法和连续或间歇dgk抑制剂给药的组合
|
|
CN117736335A
(zh)
*
|
2022-09-20 |
2024-03-22 |
深圳先进技术研究院 |
靶向间皮素和nkg2d配体的双靶向car-t细胞及其应用
|
|
WO2024062138A1
(en)
|
2022-09-23 |
2024-03-28 |
Mnemo Therapeutics |
Immune cells comprising a modified suv39h1 gene
|
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
WO2024102948A1
(en)
|
2022-11-11 |
2024-05-16 |
Celgene Corporation |
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
|
|
WO2024124132A1
(en)
|
2022-12-09 |
2024-06-13 |
Juno Therapeutics, Inc. |
Machine learning methods for predicting cell phenotype using holographic imaging
|
|
CN120712102A
(zh)
|
2022-12-13 |
2025-09-26 |
朱诺治疗学股份有限公司 |
对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
AU2024214593A1
(en)
|
2023-02-03 |
2025-08-07 |
C3S2 Gmbh |
Methods for non-viral manufacturing of engineered immune cells
|
|
KR20260005874A
(ko)
|
2023-02-28 |
2026-01-12 |
주노 쎄러퓨티크스 인코퍼레이티드 |
전신 자가면역 질환을 치료하기 위한 세포 요법
|
|
AU2024233625A1
(en)
|
2023-03-03 |
2025-09-18 |
Arsenal Biosciences, Inc. |
Systems targeting psma and ca9
|
|
WO2024220574A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
KR20250169631A
(ko)
|
2023-04-18 |
2025-12-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
|
|
WO2024220560A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
WO2024220598A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Lentiviral vectors with two or more genomes
|
|
WO2024226858A1
(en)
|
2023-04-26 |
2024-10-31 |
Juno Therapeutics, Inc. |
Methods for viral vector manufacturing
|
|
WO2024243365A2
(en)
|
2023-05-23 |
2024-11-28 |
Juno Therapeutics, Inc. |
Activation markers of t cells and method for assessing t cell activation
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
WO2025052001A1
(en)
|
2023-09-07 |
2025-03-13 |
Mnemo Therapeutics |
Methods and compositions for improving immune response
|
|
EP4520334A1
(en)
|
2023-09-07 |
2025-03-12 |
Mnemo Therapeutics |
Methods and compositions for improving immune response
|
|
WO2025059362A1
(en)
|
2023-09-13 |
2025-03-20 |
Juno Therapeutics, Inc. |
Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
|
|
WO2025076472A1
(en)
|
2023-10-06 |
2025-04-10 |
Juno Therapeutics, Inc. |
Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
|
|
WO2025096975A1
(en)
|
2023-11-02 |
2025-05-08 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods of enhancing immune cell therapies by runx2 modulation
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025128434A1
(en)
|
2023-12-14 |
2025-06-19 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for the treatment of ven/aza resistant acute myeloid leukemia
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
WO2025151838A1
(en)
|
2024-01-12 |
2025-07-17 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
WO2025163107A1
(en)
|
2024-02-01 |
2025-08-07 |
Institut Gustave Roussy |
Immune cells defective for znf217 and uses thereof
|
|
WO2025184421A1
(en)
|
2024-02-28 |
2025-09-04 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
|
|
WO2025212519A1
(en)
|
2024-04-01 |
2025-10-09 |
Moonlight Bio, Inc. |
Dll3 binding proteins and uses thereof
|
|
WO2025235851A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|
|
NL2037811B1
(en)
|
2024-05-29 |
2025-12-12 |
Univ Oslo |
Treatment for Cancer
|
|
NL2037929B1
(en)
|
2024-06-11 |
2026-01-12 |
Prinses Maxima Centrum Voor Kinderoncologie B V |
Brain Organoid
|
|
WO2026020055A2
(en)
|
2024-07-18 |
2026-01-22 |
Juno Therapeutics, Inc. |
Methods for assessing exosomes in a cell composition and related uses
|
|
WO2026020171A2
(en)
|
2024-07-19 |
2026-01-22 |
Aera Therapeutics, Inc. |
Chimeric antigen receptor constructs
|
|
WO2026025092A1
(en)
|
2024-07-26 |
2026-01-29 |
Juno Therapeutics, Inc. |
Synthetic promoters for t cell expression
|